JS Link (127120): Korean Industrials stock

What the company does

JS Link provides genomic analysis and bioinformatics services, helping decode DNA sequences to support disease prevention, diagnosis, and personalised treatment.

Its services are used in precision medicine, clinical diagnostics, and related healthcare fields, including areas such as beauty, anti-ageing, and wellness. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates across three lines: genomic analysis, personalised medicine, and diagnostic testing.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$14M

▲ +21.4% YoY

Operating profit · FY2025

−US$9M

Loss widened

Net income · FY2025

−US$11.9M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$15.9M(₩21.9B)	US$11.5M(₩15.9B)	US$14M(₩19.3B)
Operating profit	−US$3.1M(−₩4.3B)	−US$6.6M(−₩9.1B)	−US$9M(−₩12.5B)
Net income	−US$4.1M(−₩5.6B)	−US$7.8M(−₩10.8B)	−US$11.9M(−₩16.4B)

Revenue

FY2023US$15.9M
FY2024US$11.5M
FY2025US$14M

Operating profit

FY2023−US$3.1M
FY2024−US$6.6M
FY2025−US$9M

Net income

FY2023−US$4.1M
FY2024−US$7.8M
FY2025−US$11.9M

Key ratios (FY2025)

ROE

-24.0%

Debt/Eq

79.4%

Op. margin

-64.6%

Net margin

-85.1%

Rev. YoY

▲ +21.4%

Filings

All disclosures · English when translated

Price charts coming soon

Interactive price history isn't here yet. Would you use it?